Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
MercyOne Waterloo Medical Center
mi
from
Waterloo, IA
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
MercyOne Waterloo Medical Center
mi
from
Waterloo, IA
Click here to add this to my saved trials
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
A Phase I Study of BKM120 and Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
A Phase I Study of BKM120 and Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
A Phase I Study of BKM120 and Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Status: Enrolling
Updated:  12/31/1969
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
A Phase I Study of BKM120 and Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Status: Enrolling
Updated: 12/31/1969
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone
"A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone for the Treatment of Relapsed/Refractory ITP:"
Status: Enrolling
Updated:  12/31/1969
New York Presbyterian Hospital-Weill Cornell Medical College
mi
from
New York, NY
A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone
"A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone for the Treatment of Relapsed/Refractory ITP:"
Status: Enrolling
Updated: 12/31/1969
New York Presbyterian Hospital-Weill Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Monmouth
mi
from
Middletown, NJ
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Monmouth
mi
from
Middletown, NJ
Click here to add this to my saved trials
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
Click here to add this to my saved trials
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Bergen
mi
from
Montvale, NJ
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Bergen
mi
from
Montvale, NJ
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Palo Alto, CA
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
Lurie Children's Hospital
mi
from
Chicago, IL
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Lurie Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
Wayne State University School of Medicine
mi
from
Detroit, MI
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Wayne State University School of Medicine
mi
from
Detroit, MI
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
Children's Mercy Hospitals and Clinics
mi
from
Kansas City, MO
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Children's Mercy Hospitals and Clinics
mi
from
Kansas City, MO
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
DDC Clinic for Special Needs Children
mi
from
Middlefield, OH
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
DDC Clinic for Special Needs Children
mi
from
Middlefield, OH
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
Central Pennsylvania Clinic
mi
from
Strasburg, PA
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Central Pennsylvania Clinic
mi
from
Strasburg, PA
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
University of Vermont College of Medicine & University of Vermont Medical Center
mi
from
Burlington, VT
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
University of Vermont College of Medicine & University of Vermont Medical Center
mi
from
Burlington, VT
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
University of Massachusetts Medical Center
mi
from
Worcester, MA
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
University of Massachusetts Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
McMaster University
mi
from
Hamilton,
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
McMaster University
mi
from
Hamilton,
Click here to add this to my saved trials
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital of Atlanta
mi
from
Atlanta, GA
Pyruvate Kinase Deficiency Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Arizona Clinical Research Center
mi
from
Tucson, AZ
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Arizona Clinical Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Moores Cancer Centre
mi
from
La Jolla, CA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Moores Cancer Centre
mi
from
La Jolla, CA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Center
mi
from
Boulder, CO
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Center
mi
from
Boulder, CO
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
George Washington University Medical Faculty Associates
mi
from
Washington,
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
George Washington University Medical Faculty Associates
mi
from
Washington,
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
SCRI- Florida Cancer Specialists South Region
mi
from
Fort Myers, FL
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
SCRI- Florida Cancer Specialists South Region
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Carle Cancer Center
mi
from
Urbana, IL
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Indiana University Goshen Cancer Centre
mi
from
Goshen, IN
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Indiana University Goshen Cancer Centre
mi
from
Goshen, IN
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Investigative Clinical Research of Indiana
mi
from
Indianapolis, IN
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Investigative Clinical Research of Indiana
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Siouxland Hematology-Oncology Associates, L.L.P (SHOA)
mi
from
Sioux City, IA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Siouxland Hematology-Oncology Associates, L.L.P (SHOA)
mi
from
Sioux City, IA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Norton Cancer Institute, Suburban
mi
from
Louisville, KY
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Norton Cancer Institute, Suburban
mi
from
Louisville, KY
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
St. Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
St. Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Providence Cancer Institute
mi
from
Southfield, MI
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Providence Cancer Institute
mi
from
Southfield, MI
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Nebraska Hematology-Oncology, PC
mi
from
Lincoln, NE
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Nebraska Hematology-Oncology, PC
mi
from
Lincoln, NE
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Hackensack University
mi
from
Hackensack, NJ
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Hackensack University
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Hematology-Oncology Associates of Northern Jersey
mi
from
Morristown, NJ
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Hematology-Oncology Associates of Northern Jersey
mi
from
Morristown, NJ
Click here to add this to my saved trials